DP Diagnostic Products

Diagnostic Products Corporation (NYSE:DP) today reported first quarter sales of $112.9 million, a 6% increase over the first quarter of 2004. Earnings were $16.1 million, or $.54 per diluted share, an increase of 4% from $15.5 million or $.52 reported for the first quarter of 2004. The Euro and the Brazilian Real strengthened relative to the dollar, and the net effect of foreign currency movements was a 3% increase in sales. International sales increased 5% to $80.6 million while domestic sales increased 10% to $32.3 million. Sales of IMMULITE products grew 7% over the first quarter of 2004. IMMULITE product line sales reached $103.4 million for the quarter, 92% of the total sales of the Company. IMMULITE reagent sales increased 11% this quarter over the first quarter of 2004 to $90.8 million, while IMMULITE instrument and service revenue fell by 11% to $12.6 million. Sales of RIA products were $5.6 million, a 13% decline from last year's first quarter. Sales of other products were $3.9 million, up from $3.4 million in the same period last year. "We were disappointed in our instrument revenue for the quarter, however we have made significant progress on a number of other fronts. We have completed Beta testing on our Workcell and are on track for full release this quarter, we have secured new homocysteine contracts which will make up for the business we lost last year and we were informed that the FDA has accepted our corrective action plan and we are awaiting their inspection," said Michael Ziering, CEO of DPC. "Although the domestic business grew at 10%, we were below our plan, but I'm very encouraged with a number of contracts that will be coming on line over the next couple of months." The Company shipped a total of 209 IMMULITE Instruments in the first quarter including 139 IMMULITE 2000s and 2500's. The total number of IMMULITEs shipped is now over 10,000. Diagnostic Products Corporation (DPC), founded in 1971, is the global leader dedicated primarily to immunodiagnostics. DPC designs and manufacturers automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC's product menu includes a large variety of immunoassays covering a broad range of clinical disease states including over 360 specific allergens and allergy panels. Through partnerships with manufacturers of chemistry systems and reagents, DPC also addresses the chemistry and laboratory automation testing needs of its customers. DPC sells its products to hospitals, clinics and laboratories domestically and in more than 100 countries. DPC is committed to delivering to customers the highest quality products with superior service and support. The turquoise zebra icon symbolizes DPC's uniqueness in the immunodiagnostic industry as "a company that stands out." Additional Company information can be found on the Company's web site at www.dpcweb.com. Except for the historical information contained herein, this press release contains forward- looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include the effects of governmental and other actions relating to the FDA's decision that its Application Integrity Policy should be applied to the Company or relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets, including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings. -0- *T DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (Amounts in Thousands, Except Per Share Data) Three Months Ended March 31, ------------------ 2005 2004 --------- -------- SALES: Non-Affiliated Customers $107,063 $96,974 Unconsolidated Affiliates 5,848 9,109 --------- -------- Total Sales 112,911 106,083 COST OF SALES 46,738 46,022 --------- -------- Gross Profit 66,173 60,061 OPERATING EXPENSES: Selling 20,611 18,727 Research and Development 12,266 11,424 General and Administrative 12,556 9,665 Equity in Income of Affiliates (2,553) (2,130) --------- -------- OPERATING EXPENSES-NET 42,880 37,686 --------- -------- OPERATING INCOME 23,293 22,375 Interest/Other Income (Expense)-Net 174 (369) --------- -------- INCOME BEFORE INCOME TAXES AND MINORITY INTEREST 23,467 22,006 PROVISION FOR INCOME TAXES 6,993 6,602 MINORITY INTEREST 340 (53) --------- -------- NET INCOME $16,134 $15,457 ========= ======== EARNINGS PER SHARE: BASIC $0.55 $0.53 DILUTED $0.54 $0.52 WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC 29,274 28,972 DILUTED 30,105 29,944 (unaudited) *T